Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer
Clinical trial NCT03384316 · COMPLETED
Trial details
- NCT number
- NCT03384316
- Sponsor
- National Cancer Institute (NCI)
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-01-31
- Primary completion
- 2018-05-22
- Enrollment
- 11
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.